Nektar Therapeutics (NKTR) jumped +156.2% today due to positive data for its Phase 2 (REZOLVE-AD) study for Atopic Dermatitis.
There are several reasons why NKTR gapped up robustly.
First, REZOLVE-AD has major ramification for its lead drug RezPeq (an IL2 T regulatory cell stimulator).
That is to say, RezPeg is also being studied for other autoimmune diseases (i.e., alopecia areata and Type 1 Diabetes Mellitus).
Given that RezPeg cleared an important study for one indication, chances of RezPeq to clear other autoimmune diseases are significantly improved.
That’s what the market is mostly excited about.
Second, NKTR currently has $303.5M Market Cap.
That’s the price you’d have to pay to buy out the whole company.
Small-cap biotech stocks have a much better chances of increasing multiple folds for you in the next few years.
Simple reason is that it’s easier for a small company to double and triple in size than a giant.
After all, lead drug has more impact on the value of a small-cap company.
You can read more educational article here https://lnkd.in/erunxA_a. Make sure to our mailing list on Evergrowth website for educational articles.
Disclosure: we don’t own NKRT.
Disclaimer: Post serves as educational materials and NOT recommendation to buy or sell any stocks.
Best,
Dr. Harvey Tran, Evergrowth BioHealthcare Capital | Evergrowth Enterprises
Follow me on Social Media:
Enjoyed This? Stick Around! Subscribe to my newsletter for more insights on using your MD advantage in biotech investing.
Check out our Fund Presentation and our Skool Community Page.
Disclaimer: This blog is for educational and informational purposes only. It’s not a recommendation to buy, sell, or hold any stock. Always consult your investment advisor and do your due diligence before investing. In working smarter rather than harder, I wrote an initial draft based on my knowledge, experience, and insight. I then leverage AI to put the information together into this presentable format.
More Reads for You:
- Nektar Therapeutics (NKTR) Surges 156.2% on Positive Phase 2 Data for Atopic Dermatitis
- Stop Trading Stocks, Start Owning Businesses
- The Case for Long-Term Biotech Investing: My Story with Jazz Pharmaceuticals
- Red Flags to Spot Pump-and-Dump Schemes: Protect Your Wealth, Docs
- Overcoming Fear in Biotech Investing: How to Thrive Amid Volatility
- Why You Should Pay Attention to Market Cap Size For Smarter Investing
